These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 20573084)

  • 21. Icing oral mucositis: Oral cryotherapy in multiple myeloma patients undergoing autologous hematopoietic stem cell transplant.
    Chen J; Seabrook J; Fulford A; Rajakumar I
    J Oncol Pharm Pract; 2017 Mar; 23(2):116-120. PubMed ID: 26684614
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
    Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
    Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of 1-day vs 2-day dosing of high-dose melphalan followed by autologous hematopoietic cell transplantation in patients with multiple myeloma.
    Parmar SR; Bookout R; Shapiro JF; Tombleson R; Perkins J; Kim J; Yue B; Tomblyn M; Alsina M; Nishihori T
    Bone Marrow Transplant; 2014 Jun; 49(6):761-6. PubMed ID: 24662419
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of high-dose intravenous melphalan in patients undergoing peripheral blood hematopoietic progenitor-cell transplantation.
    Pinguet F; Martel P; Fabbro M; Petit I; Canal P; Culine S; Astre C; Bressolle F
    Anticancer Res; 1997; 17(1B):605-11. PubMed ID: 9066587
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral melphalan pharmacokinetics: influence of interferon-induced fever.
    Ehrsson H; Eksborg S; Wallin I; Osterborg A; Mellstedt H
    Clin Pharmacol Ther; 1990 Jan; 47(1):86-90. PubMed ID: 2295223
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The NK₁ receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myeloma.
    Egerer G; Eisenlohr K; Gronkowski M; Burhenne J; Riedel KD; Mikus G
    Br J Clin Pharmacol; 2010 Dec; 70(6):903-7. PubMed ID: 21175446
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan.
    Nieto Y; Valdez BC; Pingali SR; Bassett R; Delgado R; Nguyen J; Shah N; Popat U; Jones RB; Andersson BS; Gulbis A; Ahmed S; Bashir Q; Parmar S; Patel K; Myers A; Rondon G; Orlowski RZ; Champlin R; Qazilbash M
    Lancet Haematol; 2017 Jun; 4(6):e283-e292. PubMed ID: 28522110
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies.
    Pinguet F; Culine S; Bressolle F; Astre C; Serre MP; Chevillard C; Fabbro M
    Clin Cancer Res; 2000 Jan; 6(1):57-63. PubMed ID: 10656432
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The pharmacokinetics and pharmacodynamics of busulfan when combined with melphalan as conditioning in adult autologous stem cell transplant recipients.
    Willcox A; Wong E; Nath C; Janson B; Harrison SJ; Hoyt R; Bajel A; Shaw P; Ritchie D; Grigg A
    Ann Hematol; 2018 Dec; 97(12):2509-2518. PubMed ID: 30051172
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of melphalan 140 mg/m(2) vs 200 mg/m(2) on toxicities and outcomes in multiple myeloma patients undergoing single autologous stem cell transplantation-a single center experience.
    Katragadda L; McCullough LM; Dai Y; Hsu J; Byrne M; Hiemenz J; May S; Cogle CR; Norkin M; Brown RA; Wingard JR; Chang M; Moreb JS
    Clin Transplant; 2016 Aug; 30(8):894-900. PubMed ID: 27219740
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population pharmacokinetics of ciclosporin in haematopoietic allogeneic stem cell transplantation with emphasis on limited sampling strategy.
    Wilhelm AJ; de Graaf P; Veldkamp AI; Janssen JJ; Huijgens PC; Swart EL
    Br J Clin Pharmacol; 2012 Apr; 73(4):553-63. PubMed ID: 21988410
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1/SIOPEN trial.
    Veal GJ; Nguyen L; Paci A; Riggi M; Amiel M; Valteau-Couanet D; Brock P; Ladenstein R; Vassal G
    Eur J Cancer; 2012 Nov; 48(16):3063-72. PubMed ID: 22742881
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Population pharmacokinetics of melphalan in paediatric blood or marrow transplant recipients.
    Nath CE; Shaw PJ; Montgomery K; Earl JW
    Br J Clin Pharmacol; 2007 Aug; 64(2):151-64. PubMed ID: 17324241
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Scleromyxedema: long-term follow-up after high-dose melphalan with autologous stem cell transplantation.
    Chockalingam R; Duvic M
    Int J Dermatol; 2016 Oct; 55(10):e539-43. PubMed ID: 27207484
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Kinetics of paraprotein clearance after autografting for multiple myeloma.
    Singhal S; Powles R; Milan S; Raje N; Viner C; Treleaven J; Raymond J; Cunningham D; Mehta J
    Bone Marrow Transplant; 1995 Oct; 16(4):537-40. PubMed ID: 8528169
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Renal clearance and protein binding of melphalan in patients with cancer.
    Reece PA; Hill HS; Green RM; Morris RG; Dale BM; Kotasek D; Sage RE
    Cancer Chemother Pharmacol; 1988; 22(4):348-52. PubMed ID: 3168148
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of a method for clinical pharmacokinetic testing to allow for targeted Melphalan dosing in multiple myeloma patients undergoing autologous transplant.
    Sweiss K; Vemu B; Hofmeister CC; Wenzler E; Calip GS; Galvin JP; Mahmud N; Rondelli D; Johnson JJ; Patel P
    Br J Clin Pharmacol; 2020 Nov; 86(11):2165-2173. PubMed ID: 32285957
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship of systemic exposure to unbound docetaxel and neutropenia.
    Baker SD; Li J; ten Tije AJ; Figg WD; Graveland W; Verweij J; Sparreboom A
    Clin Pharmacol Ther; 2005 Jan; 77(1):43-53. PubMed ID: 15637530
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tobramycin disposition in ICU patients receiving a once daily regimen: population approach and dosage simulations.
    Conil JM; Georges B; Ruiz S; Rival T; Seguin T; Cougot P; Fourcade O; Pharmd GH; Saivin S
    Br J Clin Pharmacol; 2011 Jan; 71(1):61-71. PubMed ID: 21143502
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluating the adverse effects of melphalan formulations.
    Xiang E; Ni J; Glotzbecker B; Laubach J; Soiffer R; McDonnell AM
    J Oncol Pharm Pract; 2019 Oct; 25(7):1631-1637. PubMed ID: 30336728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.